Gossamer Bio Inc. (NASDAQ:GOSS) finished Wednesday with a subtraction of -$0.02 to close at $1.20, a downside of -1.64 percent. An average of 1,373,900 shares of common stock have been traded in the last five days. There was a fall of -$0.1900 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 2,855,800 shares traded, while the 50-day average volume stands at 2,637,632.
GOSS stock has decreased by -23.57% in the last month. The company shares reached their 1-month lowest point of $1.1500 on 07/27/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $0.91 and a high of $15.19 in 52 weeks. It has reached a new high 9 times so far this year and lost -44.70% or -$0.9700 in price. In spite of this, the price is down -92.10% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GOSS stock investors should be aware that Gossamer Bio Inc. (GOSS) stock had its last reported insider trading activity 49 days ago on Jun 22. In this transaction, the insider spent $2,340. EVP, Regulatory Affairs, Peterson Caryn, disposed of 7,564 shares at a price of $1.10 on Mar 16. The insider now owns more than $8,305 worth of shares. Prior to that, Chief Medical Officer Aranda Richard went on to Sale 7,563 shares at $1.10 each on Mar 16. An amount of $8,304 was transacted.
Financial Health
The quick ratio of Gossamer Bio Inc. for the three months ended June 29 was 5.20, and the current ratio was 5.20, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $13.88 million compared to revenue of $218.59 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Gossamer Bio Inc.’s return on assets was -83.20%.
Earnings Surprise
For the three-month period that ended June 29, Gossamer Bio Inc. had $125.12 million in cash and short-term investments compared to $6.44 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$42.5 million in the quarter, while revenues of -$49.17 million were shrunk -32.87%. The analyst consensus anticipated Gossamer Bio Inc.’s latest quarter earnings to come in at -$0.49 per share, but it turned out to be -$0.45, a 8.20% surprise. For the quarter, EBITDA amounted to -$46.32 million. Shareholders own equity worth $225.32 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Gossamer Bio Inc. (GOSS) price momentum. RSI 9-day as of the close on 09 August was 38.09%, suggesting the stock is Neutral, with historical volatility in this time frame at 66.16%.
As of today, GOSS’s price is $1.2680 -13.67% or -$0.1900 from its 5-day moving average. GOSS is currently trading -27.71% lower than its 20-day SMA and +14.29% higher than its 100-day SMA. However, the stock’s current price level is -7.69% below the SMA50 and -90.68% below the SMA200.
The stochastic %K and %D were 15.34% and 17.29%, respectively, and the average true range (ATR) was 0.1296. With the 14-day stochastic at 17.24% and the average true range at 0.1386, the RSI (14) stands at 42.44%. The stock has reached -0.0689 on the 9-day MACD Oscillator while the 14-day reading was at -0.0605.
Analyst Ratings
UBS downgraded Gossamer Bio Inc. (NASDAQ: GOSS) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Gossamer Bio Inc. (GOSS) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell GOSS, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is GOSS’s price target for the next 12 months?
Analysts predict a range of price targets between $1.25 and $15.00, with a median target of $4.50. Taking a look at these predictions, the average price target given by analysts for Gossamer Bio Inc. (GOSS) stock is $5.28.
